Drugs / KDT-3594
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03068481 | Feb 2017 → Aug 2018 | Parkinson disease | Kissei Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT06722729 | Dec 2024 → Jan 2026 | Parkinson disease | Kissei Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT04867551 | May → Sep 2021 | Parkinson disease | Kissei Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT03845387 | Feb 2019 → Feb 2020 | Parkinson disease | Kissei Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2020-10-09 | Kissei Pharmaceutical Co., Ltd. | 新規パーキンソン病治療薬「KDT-3594（開発番号）」のアファメド社とのライセンス契約締結に関するお知らせ kissei.co.jp ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | KDT-3594 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03068481 ↗ |
| Route | Oral | “Oral administration” NCT03068481 ↗ |